Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy I-Mab stock

Learn how to easily invest in I-Mab stock.

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 378 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in I-Mab

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

I-Mab stock price (NASDAQ: IMAB)

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

Information last updated 2022-07-02.
Latest market close$11.49
52-week range$8.05 - $81.47
50-day moving average $11.19
200-day moving average $34.86
Wall St. target price$76.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.57

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab price performance over time

Historical closes compared with the close of $11.49 from 2022-07-01

1 week (2022-06-24) -6.96%
1 month (2022-06-02) 35.34%
3 months (2022-04-01) -34.38%
6 months (2021-12-31) -75.75%
1 year (2021-07-02) -85.93%
2 years (2020-07-02) -60.81%
3 years (2019-06-28) N/A
5 years (2017-06-28) N/A

I-Mab financials

Revenue TTM $88 million
Gross profit TTM $41.6 million
Return on assets TTM -21.69%
Return on equity TTM -45.78%
Profit margin 0%
Book value $57.05
Market capitalisation $949.6 million

TTM: trailing 12 months

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab share price volatility

Over the last 12 months, I-Mab's shares have ranged in value from as little as $8.05 up to $81.47. A popular way to gauge a stock's volatility is its "beta".

IMAB.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while I-Mab's is 1.0499. This would suggest that I-Mab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd. ; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Frequently asked questions

What percentage of I-Mab is owned by insiders or institutions?
Currently 1.074% of I-Mab shares are held by insiders and 64.043% by institutions.
How many people work for I-Mab?
Latest data suggests 378 work at I-Mab.
When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December.
Where is I-Mab based?
I-Mab's address is: New Bund Center, Shanghai, China, 200124
What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030
What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site